Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on advancing innovative therapies and technologies. The company was featured in a recent article that discussed its efforts to advance Lucid-MS, an oral investigational therapy designed to inhibit demyelination and protect myelin in people with multiple sclerosis, as MS drug development increasingly expands beyond controlling inflammation toward neuroprotection and myelin preservation. Preclinical studies demonstrated myelin preservation and functional recovery in animal models, while the company’s Phase 1 program generated safety and pharmacokinetic data supporting further development. The U.S. FDA has cleared Quantum to proceed with a planned Phase 2 clinical trial in people with MS, marking a transition from early clinical development to evaluating Lucid-MS’s safety, tolerability and potential efficacy in patients. The company is also exploring myelin-focused imaging through research with Massachusetts General Hospital scientists, which could provide additional measures of myelin integrity during clinical development.
To view the full article, visit https://nnw.fm/6soWc
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer